What do AZN's past earnings surprises suggest for future quarters?

Astrazeneca's (AZN) past earnings surprises have been generally positive, suggesting that the company's future quarters may also exceed market expectations. Here's an analysis based on the latest data available:

1. **Recent Performance**: AZN's latest report period is for Q4 2024. The estimated EPS for Q1 2025 is $1.1, which represents the company's earnings per share for the upcoming quarter.

2. **Trend Analysis**: AZN's stock is currently in a bearish trend, which has lasted for 18 days. However, the continuation probability for this trend is 71%, indicating that it is likely to persist in the near term.

3. **Probability of Clear Trend**: The probability of a clear trend being established in the next 15 days is 70%, which is relatively high. This suggests that AZN's stock price is likely to experience a significant movement in either direction in the coming weeks.
4. **Unconditioned Trend Duration**: The unconditioned trend has a 50% probability duration of 11 days, which means that AZN's stock price is likely to exhibit significant momentum over the next 11 days.
5. **Market Expectations**: The estimated revenue for Q1 2025 is $13.57 billion, which is the market's expectation for AZN's revenue in the upcoming quarter. If AZN's actual revenue exceeds this estimate, it could lead to a positive earnings surprise and potentially drive the stock price higher.

In conclusion, AZN's past earnings surprises and current trend analysis suggest that the company's future quarters may also exceed market expectations. However, investors should monitor the company's performance closely, as market conditions and company-specific factors can change over time.